Poorly differentiated thyroid gland carcinoma
MONDO:0006382An adenocarcinoma arising from the thyroid gland showing only limited evidence of follicular cell differentiation. Microscopically, the adenocarcinoma cells are arranged in insular, solid, and trabecular patterns. There is associated necrosis, and vascular invasion. The prognosis depends on the tumor stage, complete or partial surgical removal of the tumor, and the degree of response to radioactive iodine therapy (adapted from WHO Tumors of Endocrine Organs, IARC Press, Lyon 2004)
Also known as: insular carcinoma, poorly differentiated carcinoma of the thyroid gland, poorly differentiated carcinoma of thyroid gland, poorly differentiated thyroid carcinoma, poorly differentiated thyroid gland cancer, poorly differentiated thyroid gland carcinoma, thyroid gland poorly differentiated carcinoma, poorly differentiated thyroid cancer
2765 clinical trials for this condition and its sub-types, 17 tagged with Poorly differentiated thyroid gland carcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
-
New combo therapy shows promise for Radioiodine-Resistant thyroid cancer
Disease control OngoingThis phase 2 trial tests a combination of the immunotherapy drug PDR001 with either trametinib or dabrafenib in 19 patients with thyroid cancer that no longer responds to radioiodine treatment. The goal is to see if the combination can shrink tumors. The study is active but no lo…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New hope for advanced thyroid cancer: personalized drug cocktails tested
Disease control OngoingThis early-phase trial tests whether giving advanced thyroid cancer patients a personalized mix of already-approved drugs, chosen based on their tumor's genetic profile, is feasible and safe. Ten patients with no other treatment options will receive individualized drug combinatio…
Phase 1 • Sponsor: Radboud University Medical Center • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Can a cancer drug make radioactive iodine work again for thyroid tumors?
Disease control OngoingThis phase 2 trial tests whether the targeted drug trametinib can help radioactive iodine (I-131) work better in people with advanced thyroid cancer that has returned or spread. The study includes 34 participants whose cancer no longer responds to standard radioactive iodine trea…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New hope for rare, aggressive thyroid cancer: drug combo shows promise
Disease control OngoingThis phase 2 trial tests whether combining lenvatinib (a targeted drug that blocks cancer growth) with pembrolizumab (an immunotherapy that helps the immune system attack cancer) can improve outcomes for people with advanced anaplastic thyroid cancer that cannot be surgically rem…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New drug cocktail shows promise for Hard-to-Treat thyroid cancer
Disease control OngoingThis phase II trial tests a combination of three drugs—cabozantinib, nivolumab, and ipilimumab—in 11 patients with advanced thyroid cancer that no longer responds to radioactive iodine or prior targeted therapy. The goal is to see if this mix can shrink tumors or stop them from g…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Immunotherapy cocktail takes on deadly thyroid cancer
Disease control OngoingThis phase 2 trial tests whether adding the immunotherapy drug atezolizumab to standard chemotherapy can help people with anaplastic or poorly differentiated thyroid cancer live longer. About 50 patients with advanced or inoperable cancer are receiving different drug combinations…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Could your own tumor cells fight cancer? new trial tests immune cell therapy
Disease control OngoingThis phase 2 trial tests a treatment called LN-145, made from a patient's own immune cells taken from their tumor. These cells are grown in a lab and then given back to the patient to attack the cancer. The study includes people with ovarian cancer, triple-negative breast cancer,…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Targeted drug before surgery shows promise for RET-Altered thyroid cancer
Disease control OngoingThis phase 2 trial tests whether giving selpercatinib before standard surgery can shrink tumors in people with RET-altered thyroid cancer. About 30 participants with advanced or recurrent disease will receive the drug and then undergo surgery. The goal is to see if the drug impro…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC